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Diabetes mellitus (DM) is a group of metabolic diseases that
is characterized by chronic hyperglycemia resulting from
defects in insulin secretion, insulin action or both [1e3]. DM
is classified as type 1 DM when beta cell destruction that
typically leads to absolute insulin deficiency is present, and
type 2 DM is secondary to insulin resistance and involves
relative insulin deficiency [4e7]. DM is diagnosed based onentre (General Organization), Saudi Arabia. Production and hosting
icense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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polydipsia, polyphagia and weight loss plus one of the
following biochemical findings: a fasting plasma glucose
level of 126 mg/dl (7.0 mmol/L), a casual plasma glucose
level of200mg/dl (11.1mmol/L), or a plasma glucose level
of 200 mg/dl (11.1 mmol/L) 2 h following an oral glucose
tolerance test. Other presenting features can include
nocturnal enuresis, blurred vision, ketoacidosis, vaginal
candidiasis, recurrent skin infections, and irritability [2].
Type 1 DM in childhood and adolescence typically progresses
through four phases: the pre-diabetes phase, the clinical
presentation of diabetes, the partial remission (or honey-
moon period), and permanent insulin dependency [3e5]. In
this summary, we will review the clinical guidelines for the
management of type 1 DM in children in Saudi Arabia.
2. Initial DM management
Newly diagnosed patients with type 1 DM should be
admitted to the hospital to initially confirm the diagnosis,
to rule out and manage DKA when present, and to provide
patient/parent education and insulin dose adjustments.
2.1. Insulin therapy
The aim of insulin therapy is to provide near physiological
insulin replacement, which is difficult with commonly used
forms of insulin and delivery methods. The availability of
new insulin analogs and alternative delivery methods (e.g.,
insulin pumps) offer more physiological insulin re-
placements. The choice of insulin type and regimen will be
guided by many factors that include the age of the patient,
the metabolic control target, patient and family education
and support, family status (e.g., stability, age of the par-
ents, size of the family, education of parents, and income),
lifestyle factors, duration of diabetes, and associated
complications including hypoglycemia. The choice of insulin
regimen should aim to provide appropriate baseline insulin
requirements over 24 h, to provide sufficient insulin levels
for meals, to achieve short-term and long-term metabolic
targets and to minimize blood glucose fluctuations.
The majority of children in Saudi Arabia are likely to be
started on twice-daily injections of insulin in the forms of a
short-acting insulin (regular insulin) and intermediate-
acting insulin (NPH) (which is not the recommended insu-
lin regimen). Insulin doses are given in quantities of 0.5e1.0
unit/kg/day. Two-thirds of the total dose is given in the
morning, and one-third is given in the evening, Two-thirds
of the dose is given as NPH, and one-third is given as regular
insulin. Patients should be observed for 3e4 days in the
hospital; simultaneously, the mother/caregiver should be
taught how to give insulin and how to monitor blood
glucose. If the patient’s condition is stable, and the
mother/caregiver is well-trained (i.e., familiar with the
signs and symptoms of hypoglycemia and how to manage
it). The patient can be discharged on twice-daily insulin
injections, frequent home blood glucose monitoring, and
close follow-up [8].
Intensifying insulin therapy using the basal-bolus
concept, i.e., either multiple daily injections (MDIs) or
continuous subcutaneous insulin infusion (CSII), has beenshown to produce the best results regarding this respect
[9e13]. Insulin is only successful as part of a comprehensive
diabetes management plan that includes diet therapy [14],
physical activity [15], education [16], rules for sick day
management [17], and psychosocial support [18,19]. Tight
control with the goal of low HbA1c levels might increase the
risk of severe hypoglycemia. However, there is evidence
that cognitive impairment is more strongly related to long-
standing hyperglycemia than to the frequency of severe
hypoglycemic attacks during intensive therapy [20].
Newer insulin analogs can be classified into rapid-acting
insulin and long-acting (basal) insulin analogs, and these
newer analogs are replacing older insulin formulations,
such as regular insulin and NPH, in the majority of clinics in
Saudi Arabia. Rapid-acting analogs, such as Novorapid
(aspart), Humalog (lispro), and Apidra (glulisine) can be
given immediately before meals because there is evidence
that the rapid actions of these analogs not only reduce
postprandial hyperglycemia but might also reduce
nocturnal hypoglycemia [21]. These insulin analogs can be
given after meals, particularly to children with unpredict-
able eating habits (e.g., infants and toddlers who are
reluctant to eat). The benefit of the use of rapid-acting
insulin analogs in children is related to the reported
reduction in hypoglycemia rather than their effects on
HbA1c [22].
Basal analogs exhibit more predictable insulin effects
with less day-to-day variation compared to NPH insulin, and
detemir (Levemir) exhibits the lowest within-subject
variability [23]. While the effects of basal analogs on
HbA1c improvement are controversial, there is evidence
that basal analogs reduce the rate of hypoglycemia and
result in greater treatment satisfaction [22]. The use of
external pumps (i.e., continuous subcutaneous insulin
infusion, CSII) is increasing. The use of such pumps is
acceptable and successful even in young infants when
adequate education and support are provided [10,12,13].
The combination of intensive insulin therapy with glucose
sensors with real-time displays is associated with a signifi-
cant improvement in HbA1c compared to conventional
blood glucose self-monitoring when the glucose sensor is
worn continuously [24]. Prevention of DKA during insulin
treatment warrants special attention as DKA is associated
with considerable mortality and morbidity [24e26]. The
potential for an increased risk of DKA due to the use of CSIIs
is still under debate because some studies have found un-
changed rates [27,28], while an increase has been observed
in a population with a low incidence of DKA [29].
2.2. Insulin dose adjustment
The majority of diabetic children require 0.5e1.0 units of
insulin/kg/day. The American Diabetes Association recom-
mends checking blood glucose four times per day; i.e.,
before meals and at bed time [5]. If the patient is on
conventional insulin therapy with regular insulin and NPH,
insulin dose adjustment depends on blood glucose moni-
toring. If the majority of morning blood glucose readings
are elevated, the evening NPH may be increased by 10%. If
the majority of the evening blood glucose readings are
elevated, the morning NPH may be increased by 10%. If the
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the morning regular insulin may be increased by 10%, and if
the majority of bed time blood glucose readings are
elevated, the evening regular insulin may be increased by
10%. The same concept can be applied in case of hypogly-
cemia. Insulin adjustment cannot succeed without proper
diet therapy that involves carbohydrates counting or at
least the exchange program [8]. If the patient is on inten-
sive insulin therapy with MDIs, 50% of the total insulin dose
may be given as basal insulin (detemir or glargine), and
rapid acting insulin dose should be calculated based on the
blood glucose readings and the amount of carbohydrates
that will be eaten. The majority of diabetic children
require one unit of rapid acting insulin for every 10e15 g of
carbohydrates as a meal bolus and one unit of rapid acting
insulin for each 50e75 mg/dl of blood glucose above the
target as a correction bolus. These ratios must be adjusted
based on pre- and 2-hour post-prandial/correction blood
glucose readings. The target range for blood glucose control
must be adjusted according to age. Old children should
have target ranges from 80 to 130 mg/dl pre-meal and
100e140e180 mg/dl post-meal. Pre-sleep readings are
recommended to be 120e150 mg/dl to avoid late night or
early morning hypoglycemia [8].
2.3. Out-patient follow-up of diabetic children
Patient, parent and care-giver education should be rein-
forced. Adjustments of insulin dosages (due to changes in
eating and exercise patterns outside the hospital and/or
the honeymoon period) are needed. At each visit, home
blood glucose readings should be discussed. Insulin doses,
the method of injection and attacks of hypoglycemia should
be evaluated. A complete clinical examination that in-
cludes weight, height and vital signs should be recorded.
Laboratory evaluations should include annual thyroid
function tests and tests for celiac disease even in the
absence of classical symptoms. Celiac disease can cause
growth failure and erratic glycemic control in diabetic pa-
tients. The prevalence of celiac disease in children with
diabetes ranges from 2.9% to 5% [6]. The most accurate
tests for celiac disease are the tests with anti-endomysial
antibodies and anti-tissue transglutaminase antibodies. If
these antibodies are not available, antigliadin antibodies
should be used. Screening tests must be repeated after 4e5
years if the initial test result is negative or if there is
clinical reason to reconsider the diagnosis of celiac disease.
The conversion rate to positivity for celiac disease declines
with time [6]. Other autoimmune diseases should be
considered if signs or symptoms specific to a disorder are
noted (e.g., adrenal insufficiency, gastric parietal cells and
gonadal signs). Tests for microalbuminuria should be used
to screen for renal impairment, and eye fundal examination
should be used to screen for retinopathy after the age of
puberty or 5 years after diagnosis. Lipid profiles may be
examined after the age of 2 years [6].
2.4. Diabetic ketoacidosis (DKA)
The classic definition of DKA is a state of hyperglycemia
>300 mg/dl, ketonemia, ketonuria, acidosis (pH < 7.3 andbicarbonate < 15 mmol/L) and glucosuria [30]. The goals of
therapy include the correction of dehydration, acidosis and
hyperglycemia and the identification and treatment of the
precipitating factors. The patient should be admitted to a
unit that has nurses who are experienced in the monitoring
and management of DKA. Laboratory tests should include
the following: CBC, electrolytes, creatinine, blood sugar,
Ca, PO4, and venous blood gases. The two main parts of
management are fluid replacement and insulin therapy. We
typically keep the patient NPO until the bicarbonate level is
>17 mmol/L. Patients with DKA usually exhibit degrees of
dehydration of 5e10%. Except under unusual circum-
stances, do not give fluids in excess of 3000 ml/m2 (i.e.,
twice maintenance) during the first 24 h. We usually
recommend 1.5e2 times maintenance normal saline. K salt
should be initiated if the patient is voiding well. Change the
IV fluid to D5% 1/2 NS when the RBS reaches 270 mg/dl. For
insulin therapy, use regular insulin with no insulin boluses.
Start insulin infusion at 0.1 units/kg/h. Insulin infusion can
be performed by mixing 50 units of regular insulin with
500 cc of normal saline. When the serum bicarbonate is
above 15, the infusion rate should be reduced to 0.05 U/kg/
h and stopped when the serum bicarbonate exceeds 18
years [8].
3. Sick day management
Intercurrent illnesses can cause high or low blood sugar [1].
All effects on patients’ glycemic control should be antici-
pated. Hypoglycemia is more commonly seen in tightly
controlled patients, and hyperglycemia is more commonly
seen in poorly controlled patients. We recommend that
insulin not be stopped (especially intermediate-acting in-
sulin and peak-less insulin) even if the patient is unable to
eat; however, dose may be adjusted. Short-acting insulin
can be stopped if severe hypoglycemia is anticipated. The
patient must be examined for the presence of symptoms
related to the underlying cause, such as infection (i.e.,
vomiting, sore throat, cough, and urinary tract infection),
surgical abdomen (i.e., appendicitis), trauma or others.
Frequent blood glucose monitoring is essential [1].
If the blood sugar is high (i.e., 200 mg/dl/11 mmol/L or
more), check for urine ketones, if negative or mildly
elevated, give 0.05e0.1 units of regular insulin/K; however,
if the urine ketones are strongly positive (þ2 or more), and
repeated blood glucose readings are increasing, the patient
should be moved to the emergency room for assessment. If
the RBS is less than 70 mg/dl, the patient should eat easily
digestible food or sugar-containing fluids. If the patient
refuses to eat or exhibits repeated vomiting, hospital
evaluation is recommended. Please note that urine strips
measure aceto-acetate (AcAc), while blood strips measure
beta-hydroxy butarate (BOHB). There may be a dissociation
between urine ketones (AcAc) and blood (BOHB) concen-
trations, which might be increased to levels consistent with
DKA even when the urine ketone test remains negative or
indicates only trace ketonuria. Blood (BOHB) concentration
measurement enables earlier identification and treatment
of ketosis compared to urine ketone testing. During reso-
lution of ketosis, blood (BOHB) normalizes sooner than
urine ketones [8].
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Approximately 50% of all patients with diabetes will un-
dergo surgery at least once in their lifetime. The manage-
ment of a child with diabetes undergoing surgery aims to
provide sufficient calories and insulin to prevent a catabolic
state and hypoglycemia. Thus, pre-operative blood glucose
control should be optimized, and frequent blood glucose
monitoring is recommended. Major surgery should be
delayed if possible when HbA1c >9%, fasting glucose
>180 mg/dl (10 mmol/L), or post-prandial glucose
>230 mg/dl (13 mmol/L). If the duration of DM is >5 years,
screening for complications that might affect surgical risks
is important. Aim for blood glucose levels of 110e180 mg/dl
(6.0e10 mmol/L). Operations are best scheduled early on
the list, preferably in the morning. We recommend giving
the evening dose of NPH as usual, giving half of that dose in
the morning and omitting the morning regular insulin if the
patient is on an NPH/regular regimen or giving half of the
long-acting insulin and omitting the rapid-acting insulin if
the patient is on an MDI regimen. For long duration sur-
geries, continuous intravenous insulin and fluid infusion are
recommended [1,8].
5. Hypoglycemia management
Hypoglycemia can develop suddenly, and, if appropriate
action is not taken, hypoglycemia can progress within a
short period of time to unconsciousness and seizure. Hy-
poglycemia can lead to cognitive defects or even directly
cause death, particularly in very young patients. It is
difficult to precisely define hypoglycemia in the pediatric
age group, and this condition is affected by many factors. It
is safe to define hypoglycemia for pediatric age group as
random blood sugar levels below 70 mg/dl (4 mmol/L) with
symptoms or signs of hypoglycemia. We can divide hypo-
glycemic attacks into mild and severe attacks. The treat-
ment of mild hypoglycemia should be provided via the oral
route. The provision of easily absorbed forms of simple
carbohydrate followed by complex long-acting carbohy-
drates is urgent for severe hypoglycemia (coma, agitation
and convulsions). People who are either unconscious or
seizing are unable to swallow, so the airway should be
secured. The person should be placed on his/her side.
Glucagon should be given immediately IM (0.5 mg for pa-
tients less than 5 years old and 1 mg for patients older than
5 years.). When the patient is awake, he should eat, and
the RBS should be monitored. The treating doctor should be
informed to allow for adjustments of the dose of insulin if
needed. If glucagon is not available, glucose gel, jam,
honey or dates should be given inside the buccal mucosa
while patient is on his left side, and the patient should be
transferred to the nearest health care center. On the way,
if he awakens, give juice with added sugar. In the emer-
gency room, the management of diabetic patients with
severe hypoglycemia is to give 2e5 ml/kg of D10% IV fol-
lowed by D10 in 1/2 normal saline at the maintenance rate
and monitor the RBS. The dose can be repeated an addition
time of the blood sugar did not increase to more than
100 mg/dl. If the patient continues to convulse or is in a
coma despite an RBS 100 mg/dl, look for other cause. Ifthe patient awakens and can tolerate oral intake, give
small amounts of rapidly absorbed carbohydrate
frequently. If well-tolerated additional complex long-acting
carbohydrate should be given orally to maintain blood
glucose levels unless a snack or mealtime is imminent, and
the IVF should be discontinued [1e3,8].
5.1. Diet therapy
The aims of nutrition therapy in type 1 DM are to optimize
the nutritional status to promote normal weight, growth
and development; to control diabetes to prevent severe
hypoglycemia and/or prolonged hyperglycemic episodes;
and to optimize blood lipid control.
Dietary recommendations should be based on healthy
eating recommendations that are suitable for all children
and adults [15] with special attention given to avoiding
sucrose and highly refined sugar. The total daily energy
intake should be distributed as follows: carbohydrates
50e55% with moderate sucrose intake (up to 10% total en-
ergy); Fat 30e35% with <10% saturated fat; and protein
10e15%. Carbohydrate counting is of great help for patients
using peak-less insulin with ultra-short-acting insulin [8].
The aims of diabetes management include achieving
optimal metabolic glycemic control, attaining normal
growth and development, eliciting the best psychosocial
adjustment, and individualizing diabetes care plans. These
aims are best achieved through a multi-disciplinary dia-
betes team approach.Conflict of Interest
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